Advertisement

Assessment of Cardiomyopathies and Cardiac Transplantation

  • Róisín B. Morgan
  • Raymond Y. KwongEmail author
Chapter
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Combining the diagnostic capabilities of CMR in the assessment of cardiac structures, myocardial perfusion, and various tissue characterizing pulse sequence methods provides a novel interrogation of myocardial physiology and abnormal anatomy from various forms of cardiomyopathy. Establishment of technical imaging standards and clinical adaptation in the past years has helped characterize the distinguishing features of different cardiomyopathies with CMR currently assuming a pivotal role in the diagnosis of cases of new-onset cardiomyopathy in experienced centers. Quantitative measurements, such as ventricular volumes, myocardial iron content, and extent of late gadolinium enhancement (LGE) can effectively monitor disease status, guide medical therapy, and impact patient outcomes in specific clinical settings. This chapter will aim to summarize these current CMR applications in the assessment of various forms of cardiomyopathy, as well as post-cardiac transplantation with case examples. It will also discuss novel methods such as T1 and T2 mapping and future directions in cardiomyopathy assessment.

Keywords

Cardiomyopathy Ischemic Dilated Hereditary Late gadolinium enhancement Fibrosis Ventricle Cardiac transplant T1/T2 mapping Edema 

References

  1. 1.
    Cahill TJ, Ashrafian H, Watkins H. Genetic cardiomyopathies causing heart failure. Circ Res. 2013;113(6):660–75.PubMedCrossRefGoogle Scholar
  2. 2.
    Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58(25):2703–38.PubMedCrossRefGoogle Scholar
  3. 3.
    Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation. 1994;90(6):2731–42.PubMedCrossRefGoogle Scholar
  4. 4.
    Erwin JP 3rd, Nishimura RA, Lloyd MA, Tajik AJ. Dual chamber pacing for patients with hypertrophic obstructive cardiomyopathy: a clinical perspective in 2000. Mayo Clin Proc. 2000;75(2):173–80.PubMedCrossRefGoogle Scholar
  5. 5.
    Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778–85.PubMedCrossRefGoogle Scholar
  6. 6.
    Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009;54(3):220–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112(6):855–61.PubMedCrossRefGoogle Scholar
  8. 8.
    Maron MS, Lesser JR, Maron BJ. Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance. Am J Cardiol. 2010;105(12):1842–3.PubMedCrossRefGoogle Scholar
  9. 9.
    Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart. 2004;90(6):645–9.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008;118(15):1541–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1(2):e000364.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Morgan RB, Kwong R. Role of cardiac MRI in the assessment of cardiomyopathy. Curr Treat Options Cardiovasc Med. 2015;17(11):53.PubMedCrossRefGoogle Scholar
  14. 14.
    Kim TK, Lee HJ, Jang HJ, Kim AY, Han JK, Choi BI. T2-weighted breath-hold MRI of the liver at 1.0 T: comparison of turbo spin-echo and HASTE sequences with and without fat suppression. J Magn Reson Imaging. 1998;8(6):1213–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Shors SM, Fung CW, Francois CJ, Finn JP, Fieno DS. Accurate quantification of right ventricular mass at MR imaging by using cine true fast imaging with steady-state precession: study in dogs. Radiology. 2004;230(2):383–8.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Lelieveldt BP, van der Geest RJ, Lamb HJ, Kayser HW, Reiber JH. Automated observer-independent acquisition of cardiac short-axis MR images: a pilot study. Radiology. 2001;221(2):537–42.PubMedCrossRefGoogle Scholar
  17. 17.
    Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343(20):1445–53.CrossRefGoogle Scholar
  18. 18.
    de Mello RA, Nacif MS, dos Santos AA, Cury RC, Rochitte CE, Marchiori E. Diagnostic performance of combined cardiac MRI for detection of coronary artery disease. Eur J Radiol. 2012;81(8):1782–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100(19):1992–2002.CrossRefGoogle Scholar
  20. 20.
    Kellman P, Arai AE. Imaging sequences for first pass perfusion – a review. J Cardiovasc Magn Reson. 2007;9(3):525–37.PubMedCrossRefGoogle Scholar
  21. 21.
    Kim RJ, Judd RM, Chen EL, Fieno DS, Parrish TB, Lima JA. Relationship of elevated 23Na magnetic resonance image intensity to infarct size after acute reperfused myocardial infarction. Circulation. 1999;100(2):185–92.PubMedCrossRefGoogle Scholar
  22. 22.
    Pegg TJ, Selvanayagam JB, Jennifer J, Francis JM, Karamitsos TD, Dall’Armellina E, et al. Prediction of global left ventricular functional recovery in patients with heart failure undergoing surgical revascularisation, based on late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:56.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Bourantas CV, Nikitin NP, Loh HP, Lukaschuk EI, Sherwi N, de Silva R, et al. Prevalence of scarred and dysfunctional myocardium in patients with heart failure of ischaemic origin: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2011;13:53.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Chalil S, Foley PW, Muyhaldeen SA, Patel KC, Yousef ZR, Smith RE, et al. Late gadolinium enhancement-cardiovascular magnetic resonance as a predictor of response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy. Europace. 2007;9(11):1031–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Cooper LT Jr. Myocarditis. N Engl J Med. 2009;360(15):1526–38.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Friedrich MG, Marcotte F. Cardiac magnetic resonance assessment of myocarditis. Circ Cardiovasc Imaging. 2013;6(5):833–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, et al. Update on myocarditis. J Am Coll Cardiol. 2012;59(9):779–92.PubMedCrossRefGoogle Scholar
  28. 28.
    Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol. 2009;53(17):1475–87.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, Carbone I, Muellerleile K, Aldrovandi A, et al. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA. 2011;306(3):277–86.PubMedCrossRefGoogle Scholar
  30. 30.
    Dall’Armellina E, Piechnik SK, Ferreira VM, Si QL, Robson MD, Francis JM, et al. Cardiovascular magnetic resonance by non contrast T1-mapping allows assessment of severity of injury in acute myocardial infarction. J Cardiovascr Magn Reson. 2012;14:15.CrossRefGoogle Scholar
  31. 31.
    h-Ici DO, Ridgway JP, Kuehne T, Berger F, Plein S, Sivananthan M, et al. Cardiovascular magnetic resonance of myocardial edema using a short inversion time inversion recovery (STIR) black-blood technique: diagnostic accuracy of visual and semi-quantitative assessment. J Cardiovasc Magn Reson. 2012;14:22.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Abdel-Aty H, Boye P, Zagrosek A, Wassmuth R, Kumar A, Messroghli D, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005;45(11):1815–22.PubMedCrossRefGoogle Scholar
  33. 33.
    Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807–16.PubMedCrossRefGoogle Scholar
  34. 34.
    Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging. 2011;4(2):150–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Bohl S, Wassmuth R, Abdel-Aty H, Rudolph A, Messroghli D, Dietz R, et al. Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of non-ischemic heart disease. Int J Cardiovasc Imaging. 2008;24(6):597–607.PubMedCrossRefGoogle Scholar
  36. 36.
    Satoh H, Sano M, Suwa K, Saitoh T, Nobuhara M, Saotome M, et al. Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis. World J Cardiol. 2014;6(7):585–601.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Machii M, Satoh H, Shiraki K, Saotome M, Urushida T, Katoh H, et al. Distribution of late gadolinium enhancement in end-stage hypertrophic cardiomyopathy and dilated cardiomyopathy: differential diagnosis and prediction of cardiac outcome. Magn Reson Imaging. 2014;32(2):118–24.PubMedCrossRefGoogle Scholar
  38. 38.
    Matoh F, Satoh H, Shiraki K, Saitoh T, Urushida T, Katoh H, et al. Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy. J Cardiac Fail. 2007;13(5):372–9.CrossRefGoogle Scholar
  39. 39.
    Kramer CM, Narula J. Viability is in the eye of the beholder. JACC Cardiovasc Imaging. 2012;5(5):574–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Puntmann VO, Voigt T, Chen Z, Mayr M, Karim R, Rhode K, et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging. 2013;6(4):475–84.PubMedCrossRefGoogle Scholar
  41. 41.
    Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122(2):138–44.PubMedCrossRefGoogle Scholar
  42. 42.
    Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242–55.PubMedCrossRefGoogle Scholar
  44. 44.
    Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54(3):201–11.PubMedCrossRefGoogle Scholar
  45. 45.
    Basso C, Thiene G, Mackey-Bojack S, Frigo AC, Corrado D, Maron BJ. Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death. Eur Heart J. 2009;30(13):1627–34.PubMedCrossRefGoogle Scholar
  46. 46.
    Zerhouni EA, Parish DM, Rogers WJ, Yang A, Shapiro EP. Human heart: tagging with MR imaging – a method for noninvasive assessment of myocardial motion. Radiology. 1988;169(1):59–63.CrossRefGoogle Scholar
  47. 47.
    Shehata ML, Cheng S, Osman NF, Bluemke DA, Lima JA. Myocardial tissue tagging with cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2009;11:55.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Pai VM, Axel L. Advances in MRI tagging techniques for determining regional myocardial strain. Curr Cardiol Rep. 2006;8(1):53–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Edvardsen T, Gerber BL, Garot J, Bluemke DA, Lima JA, Smiseth OA. Quantitative assessment of intrinsic regional myocardial deformation by Doppler strain rate echocardiography in humans: validation against three-dimensional tagged magnetic resonance imaging. Circulation. 2002;106(1):50–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Zwanenburg JJ, Kuijer JP, Marcus JT, Heethaar RM. Steady-state free precession with myocardial tagging: CSPAMM in a single breathhold. Magn Reson Med. 2003;49(4):722–30.PubMedCrossRefGoogle Scholar
  51. 51.
    Herzka DA, Guttman MA, McVeigh ER. Myocardial tagging with SSFP. Magn Reson Med. 2003;49(2):329–40.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Kramer U, Deshpande V, Fenchel M, Klumpp B, Laub G, Finn JP, et al. [Cardiac MR tagging: optimization of sequence parameters and comparison at 1.5 T and 3.0 T in a volunteer study]. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 2006;178(5):515–24. Epub 2006/04/06. Kardiales MR-Tagging: Parameteroptimierung und Sequenzvergleich bei 1.5 T und 3.0 T an einem Probandenkollektiv.Google Scholar
  53. 53.
    Chiribiri A, Leuzzi S, Conte MR, Bongioanni S, Bratis K, Olivotti L, et al. Rest perfusion abnormalities in hypertrophic cardiomyopathy: correlation with myocardial fibrosis and risk factors for sudden cardiac death. Clin Radiol. 2015;70(5):495–501.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012;14:13.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43(12):2260–4.PubMedCrossRefGoogle Scholar
  56. 56.
    Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41(9):1561–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Maron MS. Contrast-enhanced CMR in HCM: what lies behind the bright light of LGE and why it now matters. JACC Cardiovasc Imaging. 2013;6(5):597–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Kwong RY, Farzaneh-Far A. Measuring myocardial scar by CMR. JACC Cardiovasc Imaging. 2011;4(2):157–60.PubMedCrossRefGoogle Scholar
  59. 59.
    Harrigan CJ, Peters DC, Gibson CM, Maron BJ, Manning WJ, Maron MS, et al. Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Radiology. 2011;258(1):128–33.PubMedCrossRefGoogle Scholar
  60. 60.
    Ho CY, Abbasi SA, Neilan TG, Shah RV, Chen Y, Heydari B, et al. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013;6(3):415–22.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114(3):216–25.PubMedCrossRefGoogle Scholar
  62. 62.
    Azaouagh A, Churzidse S, Konorza T, Erbel R. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a review and update. Clin Res Cardiol. 2011;100(5):383–94.PubMedCrossRefGoogle Scholar
  63. 63.
    Heermann P, Hedderich DM, Paul M, Schulke C, Kroeger JR, Baessler B, et al. Biventricular myocardial strain analysis in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) using cardiovascular magnetic resonance feature tracking. J Cardiovasc Magn Reson. 2014;16:75.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121(13):1533–41.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Frans van Hoorn JP, Spears D, Nguyen ET, Wald RM, Ley S, Torres FS, et al. Low diagnostic yield of Late Gadolinium Enhancement (LGE) in screening patients with suspected Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) by Cardiovascular Magnetic Resonance (CMR). J Cardiovasc Magn Reson. 2012;14(Suppl 1):141.CrossRefGoogle Scholar
  66. 66.
    Bluemke DA. ARVC: imaging diagnosis is still in the eye of the beholder. JACC Cardiovasc Imaging. 2011;4(3):288–91.PubMedCrossRefGoogle Scholar
  67. 67.
    Grant RT. An unusual anomaly of the coronary vessels in the malformed heart of a child. Heart. 1926;13:273–83.Google Scholar
  68. 68.
    Freedom RM, Yoo SJ, Perrin D, Taylor G, Petersen S, Anderson RH. The morphological spectrum of ventricular noncompaction. Cardiol Young. 2005;15(4):345–64.PubMedCrossRefGoogle Scholar
  69. 69.
    Zhang W, Chen H, Qu X, Chang CP, Shou W. Molecular mechanism of ventricular trabeculation/compaction and the pathogenesis of the left ventricular noncompaction cardiomyopathy (LVNC). Am J Med Genet C Semin Med Genet. 2013;163C(3):144–56.PubMedCrossRefGoogle Scholar
  70. 70.
    Bax JJ, Atsma DE, Lamb HJ, Rebergen SA, Bootsma M, Voogd PJ, et al. Noninvasive and invasive evaluation of noncompaction cardiomyopathy. J Cardiovasc Magn Reson. 2002;4(3):353–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Weiford BC, Subbarao VD, Mulhern KM. Noncompaction of the ventricular myocardium. Circulation. 2004;109(24):2965–71.PubMedCrossRefGoogle Scholar
  72. 72.
    Roberts WC, Karia SJ, Ko JM, Grayburn PA, George BA, Hall SA, et al. Examination of isolated ventricular noncompaction (hypertrabeculation) as a distinct entity in adults. Am J Cardiol. 2011;108(5):747–52.PubMedCrossRefGoogle Scholar
  73. 73.
    Murphy RT, Thaman R, Blanes JG, Ward D, Sevdalis E, Papra E, et al. Natural history and familial characteristics of isolated left ventricular non-compaction. Eur Heart J. 2005;26(2):187–92.PubMedCrossRefGoogle Scholar
  74. 74.
    Petersen SE, Selvanayagam JB, Wiesmann F, Robson MD, Francis JM, Anderson RH, et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol. 2005;46(1):101–5.PubMedCrossRefGoogle Scholar
  75. 75.
    Daimon Y, Watanabe S, Takeda S, Hijikata Y, Komuro I. Two-layered appearance of noncompaction of the ventricular myocardium on magnetic resonance imaging. Circ J. 2002;66(6):619–21.PubMedCrossRefGoogle Scholar
  76. 76.
    Alsaileek AA, Syed I, Seward JB, Julsrud P. Myocardial fibrosis of left ventricle: magnetic resonance imaging in noncompaction. J Magn Reson Imaging. 2008;27(3):621–4.PubMedCrossRefGoogle Scholar
  77. 77.
    Klaassen S, Probst S, Oechslin E, Gerull B, Krings G, Schuler P, et al. Mutations in sarcomere protein genes in left ventricular noncompaction. Circulation. 2008;117(22):2893–901.PubMedCrossRefGoogle Scholar
  78. 78.
    Shemisa K, Li J, Tam M, Barcena J. Left ventricular noncompaction cardiomyopathy. Cardiovasc Diag Ther. 2013;3(3):170–5.Google Scholar
  79. 79.
    Oechslin EN, Attenhofer Jost CH, Rojas JR, Kaufmann PA, Jenni R. Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis. J Am Coll Cardiol. 2000;36(2):493–500.PubMedCrossRefGoogle Scholar
  80. 80.
    Ritter M, Oechslin E, Sutsch G, Attenhofer C, Schneider J, Jenni R. Isolated noncompaction of the myocardium in adults. Mayo Clin Proc. 1997;72(1):26–31.PubMedCrossRefGoogle Scholar
  81. 81.
    Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36(4):244–51.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Duston MA, Skinner M, Shirahama T, Cohen AS. Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years’ experience. Am J Med. 1987;82(3):412–4.PubMedCrossRefGoogle Scholar
  83. 83.
    Falk RH, Skinner M. The systemic amyloidoses: an overview. Adv Intern Med. 2000;45:107–37.PubMedGoogle Scholar
  84. 84.
    Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186–93.PubMedCrossRefGoogle Scholar
  85. 85.
    vanden Driesen RI, Slaughter RE, Strugnell WE. MR findings in cardiac amyloidosis. Am J Roentgenol. 2006;186(6):1682–5.CrossRefGoogle Scholar
  86. 86.
    Pandey T, Jambhekar K, Shaikh R, Lensing S, Viswamitra S. Utility of the inversion scout sequence (TI scout) in diagnosing myocardial amyloid infiltration. Int J Cardiovasc Imaging. 2013;29(1):103–12.PubMedCrossRefGoogle Scholar
  87. 87.
    Xia R, Gao F, Sun J, Xia C, Hu Z, Guo Y. Cardiac magnetic resonance imaging of systemic amyloidosis patients with normal left ventricular ejection fraction: an initial study. Pak J Med Sci. 2013;29(6):1300–5.PubMedPubMedCentralGoogle Scholar
  88. 88.
    Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3(2):155–64.PubMedCrossRefGoogle Scholar
  89. 89.
    Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6(4):488–97.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Brooks J, Kramer CM, Salerno M. Markedly increased volume of distribution of gadolinium in cardiac amyloidosis demonstrated by T1 mapping. J Magn Reson Imaging. 2013;38(6):1591–5.PubMedCrossRefGoogle Scholar
  91. 91.
    Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6(1):34–9.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997;336(17):1224–34.PubMedCrossRefGoogle Scholar
  93. 93.
    Johns CJ, Scott PP, Schonfeld SA. Sarcoidosis. Annu Rev Med. 1989;40:353–71.PubMedCrossRefGoogle Scholar
  94. 94.
    Sekhri V, Sanal S, Delorenzo LJ, Aronow WS, Maguire GP. Cardiac sarcoidosis: a comprehensive review. Arch Med Sci. 2011;7(4):546–54.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Houston BA, Mukherjee M. Cardiac sarcoidosis: clinical manifestations, imaging characteristics, and therapeutic approach. Clin Med Insights Cardiol. 2014;8(Suppl 1):31–7.PubMedPubMedCentralGoogle Scholar
  96. 96.
    Lewin RF, Mor R, Spitzer S, Arditti A, Hellman C, Agmon J. Echocardiographic evaluation of patients with systemic sarcoidosis. Am Heart J. 1985;110(1 Pt 1):116–22.PubMedCrossRefGoogle Scholar
  97. 97.
    Lam CS, Tolep KA, Metke MP, Glockner J, Cooper LT Jr. Coronary sarcoidosis presenting as acute coronary syndrome. Clin Cardiol. 2009;32(6):E68–71.PubMedCrossRefGoogle Scholar
  98. 98.
    Garrett J, O’Neill H, Blake S. Constrictive pericarditis associated with sarcoidosis. Am Heart J. 1984;107(2):394.PubMedCrossRefGoogle Scholar
  99. 99.
    Mantini N, Williams B Jr, Stewart J, Rubinsztain L, Kacharava A. Cardiac sarcoid: a clinician’s review on how to approach the patient with cardiac sarcoid. Clin Cardiol. 2012;35(7):410–5.PubMedCrossRefGoogle Scholar
  100. 100.
    Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145(3):234–41.PubMedCrossRefGoogle Scholar
  101. 101.
    Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58(6):1204–11.PubMedCrossRefGoogle Scholar
  102. 102.
    Doughan AR, Williams BR. Cardiac sarcoidosis. Heart. 2006;92(2):282–8.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015;131(7):624–32.PubMedCrossRefGoogle Scholar
  104. 104.
    Greulich S, Deluigi CC, Gloekler S, Wahl A, Zurn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6(4):501–11.PubMedCrossRefGoogle Scholar
  105. 105.
    Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45(10):1683–90.PubMedCrossRefGoogle Scholar
  106. 106.
    Kim JS, Judson MA, Donnino R, Gold M, Cooper LT Jr, Prystowsky EN, et al. Cardiac sarcoidosis. Am Heart J. 2009;157(1):9–21.PubMedCrossRefGoogle Scholar
  107. 107.
    Vignaux O. Cardiac sarcoidosis: spectrum of MRI features. Am J Roentgenol. 2005;184(1):249–54.CrossRefGoogle Scholar
  108. 108.
    Nagueh SF. Fabry disease. Heart. 2003;89(8):819–20.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6(3):392–8.PubMedCrossRefGoogle Scholar
  110. 110.
    Steel KE, Kwong RY. Application of cardiac magnetic resonance imaging in cardiomyopathy. Curr Heart Fail Rep. 2008;5(3):128–35.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18(1):33–9.PubMedCrossRefGoogle Scholar
  112. 112.
    He T, Gatehouse PD, Kirk P, Mohiaddin RH, Pennell DJ, Firmin DN. Myocardial T*2 measurement in iron-overloaded thalassemia: an ex vivo study to investigate optimal methods of quantification. Magn Reson Med. 2008;60(2):350–6.PubMedCrossRefGoogle Scholar
  113. 113.
    Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961–8.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Guo H, Au WY, Cheung JS, Kim D, Jensen JH, Khong PL, et al. Myocardial T2 quantitation in patients with iron overload at 3 Tesla. J Magn Reson Imaging. 2009;30(2):394–400.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol. 2011;58(7):659–70.PubMedCrossRefGoogle Scholar
  116. 116.
    Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, et al. Shared genetic predisposition in Peripartum and dilated cardiomyopathies. N Engl J Med. 2016;374(3):233–41.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Mitchell JH, Hadden TB, Wilson JM, Achari A, Muthupillai R, Flamm SD. Clinical features and usefulness of cardiac magnetic resonance imaging in assessing myocardial viability and prognosis in Takotsubo cardiomyopathy (transient left ventricular apical ballooning syndrome). Am J Cardiol. 2007;100(2):296–301.PubMedCrossRefGoogle Scholar
  118. 118.
    Scholte AJ, Bax JJ, Stokkel MP, Plokker T, Kaandorp TA, Lamb HJ, et al. Multimodality imaging to diagnose takotsubo cardiomyopathy. J Nuclear Cardiol. 2006;13(1):123–6.CrossRefGoogle Scholar
  119. 119.
    Schwitter J, Wacker CM, Wilke N, Al-Saadi N, Sauer E, Huettle K, et al. MR-IMPACT II: Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary artery disease Trial: perfusion-cardiac magnetic resonance vs. single-photon emission computed tomography for the detection of coronary artery disease: a comparative multicentre, multivendor trial. Eur Heart J. 2013;34(10):775–81.PubMedCrossRefGoogle Scholar
  120. 120.
    Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet. 2012;379(9814):453–60.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Daly C, Kwong RY. Cardiac MRI for myocardial ischemia. Methodist Debakey Cardiovasc J. 2013;9(3):123–31.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Pennell DJ, Underwood SR, Manzara CC, Swanton RH, Walker JM, Ell PJ, et al. Magnetic resonance imaging during dobutamine stress in coronary artery disease. Am J Cardiol. 1992;70(1):34–40.PubMedCrossRefGoogle Scholar
  123. 123.
    Rerkpattanapipat P, Gandhi SK, Darty SN, Williams RT, Davis AD, Mazur W, et al. Feasibility to detect severe coronary artery stenoses with upright treadmill exercise magnetic resonance imaging. Am J Cardiol. 2003;92(5):603–6.PubMedCrossRefGoogle Scholar
  124. 124.
    Pennell DJ, Underwood SR, Ell PJ, Swanton RH, Walker JM, Longmore DB. Dipyridamole magnetic resonance imaging: a comparison with thallium-201 emission tomography. Br Heart J. 1990;64(6):362–9.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Paetsch I, Jahnke C, Wahl A, Gebker R, Neuss M, Fleck E, et al. Comparison of dobutamine stress magnetic resonance, adenosine stress magnetic resonance, and adenosine stress magnetic resonance perfusion. Circulation. 2004;110(7):835–42.PubMedCrossRefGoogle Scholar
  126. 126.
    Nagel E, Lehmkuhl HB, Bocksch W, Klein C, Vogel U, Frantz E, et al. Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography. Circulation. 1999;99(6):763–70.PubMedCrossRefGoogle Scholar
  127. 127.
    Hundley WG, Hamilton CA, Thomas MS, Herrington DM, Salido TB, Kitzman DW, et al. Utility of fast cine magnetic resonance imaging and display for the detection of myocardial ischemia in patients not well suited for second harmonic stress echocardiography. Circulation. 1999;100(16):1697–702.PubMedCrossRefGoogle Scholar
  128. 128.
    Hundley WG, Morgan TM, Neagle CM, Hamilton CA, Rerkpattanapipat P, Link KM. Magnetic resonance imaging determination of cardiac prognosis. Circulation. 2002;106(18):2328–33.PubMedCrossRefGoogle Scholar
  129. 129.
    Wellnhofer E, Olariu A, Klein C, Grafe M, Wahl A, Fleck E, et al. Magnetic resonance low-dose dobutamine test is superior to SCAR quantification for the prediction of functional recovery. Circulation. 2004;109(18):2172–4.PubMedCrossRefGoogle Scholar
  130. 130.
    Gutberlet M, Frohlich M, Mehl S, Amthauer H, Hausmann H, Meyer R, et al. Myocardial viability assessment in patients with highly impaired left ventricular function: comparison of delayed enhancement, dobutamine stress MRI, end-diastolic wall thickness, and TI201-SPECT with functional recovery after revascularization. Eur Radiol. 2005;15(5):872–80.PubMedCrossRefGoogle Scholar
  131. 131.
    Bodi V, Sanchis J, Nunez J, Mainar L, Lopez-Lereu MP, Monmeneu JV, et al. Prognostic value of a comprehensive cardiac magnetic resonance assessment soon after a first ST-segment elevation myocardial infarction. JACC Cardiovasc Imaging. 2009;2(7):835–42.PubMedCrossRefGoogle Scholar
  132. 132.
    Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48(10):1977–85.PubMedCrossRefGoogle Scholar
  133. 133.
    Lehrke S, Lossnitzer D, Schob M, Steen H, Merten C, Kemmling H, et al. Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart. 2011;97(9):727–32.PubMedCrossRefGoogle Scholar
  134. 134.
    Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51(25):2414–21.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Sen-Chowdhry S, Prasad SK, Syrris P, Wage R, Ward D, Merrifield R, et al. Cardiovascular magnetic resonance in arrhythmogenic right ventricular cardiomyopathy revisited: comparison with task force criteria and genotype. J Am Coll Cardiol. 2006;48(10):2132–40.PubMedCrossRefGoogle Scholar
  136. 136.
    Tandri H, Saranathan M, Rodriguez ER, Martinez C, Bomma C, Nasir K, et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol. 2005;45(1):98–103.PubMedCrossRefGoogle Scholar
  137. 137.
    Vermes E, Strohm O, Otmani A, Childs H, Duff H, Friedrich MG. Impact of the revision of arrhythmogenic right ventricular cardiomyopathy/dysplasia task force criteria on its prevalence by CMR criteria. JACC Cardiovasc Imaging. 2011;4(3):282–7.PubMedCrossRefGoogle Scholar
  138. 138.
    Parsai C, O’Hanlon R, Prasad SK, Mohiaddin RH. Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies. J Cardiovasc Magn Reson. 2012;14:54.PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Leonardi S, Raineri C, De Ferrari GM, Ghio S, Scelsi L, Pasotti M, et al. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy. Eur Heart J. 2009;30(16):2003–10.PubMedCrossRefGoogle Scholar
  140. 140.
    van Rijsingen IA, Bekkers SC, Schalla S, Hermans-van Ast JF, Snoep G, Alzand BS, et al. Exercise related ventricular arrhythmias are related to cardiac fibrosis in hypertrophic cardiomyopathy mutation carriers. Neth Heart J. 2011;19(4):168–74.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail. 2008;1(3):184–91.PubMedCrossRefGoogle Scholar
  142. 142.
    Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56(11):875–87.PubMedCrossRefGoogle Scholar
  143. 143.
    Sharma S. Cardiac imaging in myocardial sarcoidosis and other cardiomyopathies. Curr Opin Pulm Med. 2009;15(5):507–12.PubMedCrossRefGoogle Scholar
  144. 144.
    Manins V, Habersberger J, Pfluger H, Taylor AJ. Cardiac magnetic resonance imaging in the evaluation of cardiac sarcoidosis: an Australian single-centre experience. Int Med J. 2009;39(2):77–82.CrossRefGoogle Scholar
  145. 145.
    Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120(20):1969–77.PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    Patel AR, Klein MR, Chandra S, Spencer KT, Decara JM, Lang RM, et al. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. Eur J Heart Fail. 2011;13(11):1231–7.PubMedCrossRefGoogle Scholar
  147. 147.
    Shimada T, Shimada K, Sakane T, Ochiai K, Tsukihashi H, Fukui M, et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med. 2001;110(7):520–7.PubMedCrossRefGoogle Scholar
  148. 148.
    Wisenberg G, Pflugfelder PW, Kostuk WJ, McKenzie FN, Prato FS. Diagnostic applicability of magnetic resonance imaging in assessing human cardiac allograft rejection. Am J Cardiol. 1987;60(1):130–6.PubMedCrossRefGoogle Scholar
  149. 149.
    Marie PY, Angioi M, Carteaux JP, Escanye JM, Mattei S, Tzvetanov K, et al. Detection and prediction of acute heart transplant rejection with the myocardial T2 determination provided by a black-blood magnetic resonance imaging sequence. J Am Coll Cardiol. 2001;37(3):825–31.PubMedCrossRefGoogle Scholar
  150. 150.
    Estep JD, Shah DJ, Nagueh SF, Mahmarian JJ, Torre-Amione G, Zoghbi WA. The role of multimodality cardiac imaging in the transplanted heart. JACC Cardiovasc Imaging. 2009;2(9):1126–40.PubMedCrossRefGoogle Scholar
  151. 151.
    Steen H, Merten C, Refle S, Klingenberg R, Dengler T, Giannitsis E, et al. Prevalence of different gadolinium enhancement patterns in patients after heart transplantation. J Am Coll Cardiol. 2008;52(14):1160–7.PubMedCrossRefGoogle Scholar
  152. 152.
    Miller CA, Sarma J, Naish JH, Yonan N, Williams SG, Shaw SM, et al. Multiparametric cardiovascular magnetic resonance assessment of cardiac allograft vasculopathy. J Am Coll Cardiol. 2014;63(8):799–808.PubMedCrossRefGoogle Scholar
  153. 153.
    Germain P, El Ghannudi S, Jeung MY, Ohlmann P, Epailly E, Roy C, et al. Native T1 mapping of the heart – a pictorial review. Clin Med Insights Cardiol. 2014;8(Suppl 4):1–11.PubMedPubMedCentralGoogle Scholar
  154. 154.
    Messroghli DR, Walters K, Plein S, Sparrow P, Friedrich MG, Ridgway JP, et al. Myocardial T1 mapping: application to patients with acute and chronic myocardial infarction. Magn Reson Med. 2007;58(1):34–40.CrossRefGoogle Scholar
  155. 155.
    h-Ici DO, Jeuthe S, Al-Wakeel N, Berger F, Kuehne T, Kozerke S, et al. T1 mapping in ischaemic heart disease. Eur Heart J Cardiovasc Imaging. 2014;15(6):597–602.PubMedCrossRefGoogle Scholar
  156. 156.
    Ferreira VM, Piechnik SK, Dall’Armellina E, Karamitsos TD, Francis JM, Choudhury RP, et al. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:42.PubMedPubMedCentralCrossRefGoogle Scholar
  157. 157.
    Ferreira VM, Piechnik SK, Dall’Armellina E, Karamitsos TD, Francis JM, Ntusi N, et al. Native T1-mapping detects the location, extent and patterns of acute myocarditis without the need for gadolinium contrast agents. J Cardiovasc Magn Reson. 2014;16:36.PubMedPubMedCentralCrossRefGoogle Scholar
  158. 158.
    Ferreira VM, Piechnik SK, Dall’Armellina E, Karamitsos TD, Francis JM, Ntusi N, et al. T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. JACC Cardiovasc Imaging. 2013;6(10):1048–58.PubMedCrossRefGoogle Scholar
  159. 159.
    Mirakhur A, Anca N, Mikami Y, Merchant N. T2-weighted imaging of the heart – a pictorial review. Eur J Radiol. 2013;82(10):1755–62.PubMedCrossRefGoogle Scholar
  160. 160.
    Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113(5):671–8.PubMedCrossRefGoogle Scholar
  161. 161.
    Cheong BY, Muthupillai R. Nephrogenic systemic fibrosis: a concise review for cardiologists. Texas Heart Inst J/from the Texas Heart Institute of St Luke’s Episcopal Hospital, Texas Children’s Hospital. 2010;37(5):508–15.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Non-invasive Cardiovascular Imaging, Cardiovascular Division, Department of MedicineBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations